# Characterization of diffuse large B-cell lymphoma subgroups by metabolomic analyses

Nathalie Lacrampe, Emeline Chu-Van, Sylvain Dechaumet, Aurélie Montagne, Cédric Caradeuc, Covadonga Lucas-Torres, Gildas Bertho, Véronique Baud, Florence Castelli, Christophe Junot, et al.

<figure><img src="image_1.png" /></figure>

## ► To cite this version:

Nathalie Lacrampe, Emeline Chu-Van, Sylvain Dechaumet, Aurélie Montagne, Cédric Caradeuc, et al. Characterization of diffuse large B-cell lymphoma subgroups by metabolomic analyses. 16e Journées Scientifiques du Réseau Francophone de Métabolomique et de Fluxomique, Jun 2024, Saint-Malo, France. hal-05149277

HAL Id: hal-05149277

https://hal.science/hal-05149277v1

Submitted on 7 Jul 2025

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_2.png" /></figure>
# Characterization of diffuse large B-cell lymphoma subgroups by metabolomic analyses

Nathalie Lacrampe*<fnref n="1" />, Emeline Chu-Van<fnref n="1" />, Sylvain Dechaumet<fnref n="1" />, Aurélie Montagne<fnref n="2" />, Cédric Caradeuc<fnref n="3" />, Covadonga Lucas-Torres<fnref n="3" />, Gildas Bertho<fnref n="3" />, Véronique Baud<fnref n="2" />, Florence Castelli<fnref n="1" />, Christophe Junot<fnref n="1" />, François Fenaille<fnref n="1" />, Nicolas Giraud<fnref n="3" />, and Annelaure Damont†<fnref n="1" />

## Résumé

Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive form of lymphoma and characterized by a high heterogeneity. Despite recent advances, 40% of patients do not respond to conventional treatment and relapse, leading to death. Research has shown that the dysregulation of cancer cell metabolism can be targeted to overcome treatment resistance and lead to a personalized medicine. In this context, and in order to better characterize DLBCL cell lines, the first results of metabolomic analyses using high-resolution mass spectrometry coupled to liquid chromatography (LC-HRMS) will be presented. Metabolic extracts from the intra- and extra-cellular compartments of seven DLBCL cell lines were obtained and subjected to LC-HRMS profiling using an Orbitrap Fusion coupled to HILIC column separation. Among the 2,500 robust metabolic variables obtained in the LC-HRMS datasets, over 180 metabolites were identified, and some 20 of these proved significantly modulated specifically to the metabolism of the different lines. With the broader aim of developing and validating approaches combining mass spectrometry and ultra-high-resolution NMR to define new subgroups of DLBCL patients, the first MS / NMR cross-observations will be presented to highlight the points of convergence and the complementary nature of both techniques. These preliminary results, which will be refined and extended to the analysis of cell metabolism in the presence of drugs in the remainder of the project, pave the way for new diagnostic and then therapeutic options.

<footnote n="1">¹Laboratoire innovations en spectrométrie de masse pour la santé – Service de Pharmacologie et d'Immunoanalyse, CEA, INRA, Université Paris Saclay, MetaboHUB, Gif-sur-Yvette, France – France</footnote>

<footnote n="2">²NF-kappaB, Différenciation et Cancer – Université Paris Cité, Paris, France – France</footnote>

<footnote n="3">³Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques – Université Paris Cité, Paris, France – France</footnote>

<footnote>*Intervenant</footnote>

<footnote>†Auteur correspondant: annelaure.damont@cea.fr</footnote>